{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:21:30Z","timestamp":1783938090537,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2222,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/jto.0b013e3181ba31e0","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T07:19:24Z","timestamp":1256627964000},"page":"1404-1414","source":"Crossref","is-referenced-by-count":32,"title":["Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Robert","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Muehlenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astra M.","family":"Liepa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Babineaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Wielage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181ba31e0_bib1","series-title":"Cancer Facts & Figures 2008","author":"American Cancer Society","year":"2008"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib3","article-title":"NCCN Clinical Practice Guidelines in Oncology","volume":"2","author":"National Comprehensive Cancer Network","year":"2008","journal-title":"Non-Small Cell Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2004.09.053","article-title":"American Society of Clinical Oncology treatment of unresectable non\u2013small-cell lung cancer guideline: update 2003","volume":"22","author":"Pfister","year":"2004","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1097\/JTO.0b013e3181ba31e0_bib5","doi-asserted-by":"crossref","first-page":"277S","DOI":"10.1378\/chest.07-1381","article-title":"Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)","volume":"132","author":"Socinski","year":"2007","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1097\/JTO.0b013e3181ba31e0_bib6","doi-asserted-by":"crossref","first-page":"226S","DOI":"10.1378\/chest.123.1_suppl.226S","article-title":"Chemotherapeutic management of stage IV non-small cell lung cancer","volume":"123","author":"Socinski","year":"2003","journal-title":"Chest"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/thorax.57.1.20","article-title":"Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review","volume":"57","author":"Clegg","year":"2002","journal-title":"Thorax"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib8","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2004.10.014","article-title":"Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes","volume":"47","author":"Le Chevalier","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib10","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib11","author":"Eli Lilly and Company"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib12","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib13","doi-asserted-by":"crossref","unstructured":"Pimentel FL, von Pawel J, Martins RG, et al. Resource Utilization by Non-Small Cell Lung Cancer Histology: Results from the Randomized, Phase III Trial of Pemetrexed\/Cisplatin Versus Gemcitabine\/Cisplatin. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology Chicago, IL, May 30, 2008\u2013June 3, 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.8097"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","article-title":"Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial","volume":"357","author":"Georgoulias","year":"2001","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib15","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid, is an inhibitor of thymidylate synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J Med Chem"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib16","first-page":"437","article-title":"Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514","volume":"19","author":"Schultz","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/mol.104.009373","article-title":"Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells","volume":"68","author":"Giovannetti","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0006-2952(03)00287-9","article-title":"Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression","volume":"66","author":"Sigmond","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","article-title":"Outcomes of cancer treatment for technology assessment and cancer treatment guidelines","volume":"14","author":"American Society of Clinical Oncology (ASCO)","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib20","unstructured":"Vansteenkiste J, Edelman MJ, de Marinis F, et al. Indirect Comparison of Pemetrexed Plus Cisplatin with Other Platinum-Based Therapies for First-Line Advanced Non-Small Cell Lung Cancer [Abstract]. Proceedings of the Internal Thoracic Oncolog Congress, Dresden, 2008."},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib22","author":"Centers for Medicare & Medicaid Services (CMS)"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib23","author":"National Cancer Institute (NCI)"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib24","author":"Genentech"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib25","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1200\/jco.2006.24.18_suppl.6057","article-title":"Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer [abstract]","volume":"24","author":"Grusenmeyer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00019053-200220050-00004","article-title":"Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer","volume":"20","author":"Lees","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2165\/00019053-200523110-00007","article-title":"Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer","volume":"23","author":"Neymark","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib28","doi-asserted-by":"crossref","unstructured":"Gralla RJ, Grusenmeyer PA, Brooks BJ. Evaluating the costs and cost-effectiveness of new regimens for non-small cell lung cancer (NSCLC) [abstract]. 33rd Proceedings of the American Society of Clinical Oncology, 1997, Denver, CO: 1501.","DOI":"10.1016\/S0959-8049(97)85940-0"},{"key":"10.1097\/JTO.0b013e3181ba31e0_bib29","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/00019053-200119110-00005","article-title":"Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer","volume":"19","author":"Plosker","year":"2001","journal-title":"Pharmacoeconomics"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T07:54:15Z","timestamp":1590220455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415312569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S1556086415312569"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181ba31e0","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}